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1. ‘‘Cancer is too complex to permit drug discovery’’ biological or pathological complexity must be addressedA pessimistic view of the prospects for the discovery of
selective chemotherapies for metastatic cancer would sug-
gest that the molecular pathology of cancer is overwhelm-
ingly complex. This pessimism stems from a variety of
observations. Karyotype analysis of solid tumors, such as
those of the colon, shows gross instability, with chromo-
somes in an apparently chaotic condition and the tumor in a
state of permanent, unstable evolution [1]. Analysis of
mutations in colon cancer, by the polymerase chain reaction,
showed that there are upwards of 11,000 mutations in
premalignant lesions [2,3]. And in a recent review, Loeb
et al. [4], surveying the evidence that tumors have a
‘‘mutator phenotype’’, suggest that in a tumor of 108 cells,
there are a billion different mutations. This presents a bleak
outlook for a single, targeted therapy. It is thus considered
that there is little chance to find one or two agents which,
like antibiotics, could have a significant impact on such a
complex, unstable disease. Moreover, those who suggest
that each lesion, amongst tens or hundreds, should have a
specific inhibitor targeted to it, do not seem to appreciate the
practicalities of polypharmacy nor its economics, particu-
larly with respect to clinical trials.2. From thousands to five and from five to two
However, one may wonder whether the complexities of
cancer—or indeed of biology itself—are as insoluble as
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complex problems in other fields [7]. Such sentiments
permitted Reddy and Kaelin [8] to propose that a small
number of targeted therapies are in fact a reality, since
there are estimates that only five to ten causal mutations
are necessary in the evolution of solid tumors [9], the rest
being epiphenomenal changes. Indeed, recent experiments
in transgenic mice support the view that metastatic tumors
can be generated by a limited number of lesions. The
results suggest that massive genomic instability is not
necessary for tumor evolution and that progression from
the initiating carcinogenic events to dependency on others
is not necessary. Indeed, the idea that genomic instability
is a key signature of cancer is hotly debated [10]. Thus, for
tumor initiation and progression in the murine pancreas,
Evan and colleagues showed, in ground-breaking experi-
ments, that only two genetic changes needed to be engi-
neered: the expression of a multifunctional oncogene (c-
myc) and the inhibition of c-myc-induced apoptosis by
targeted expression of the anti-apoptotic Bcl-XL [11].
Subsequent suppression of c-myc expression in vivo, in
animals with metastatic pancreatic tumors, resulted in
complete tumor regression and the collapse of tumor
neovasculature. Indeed, several similar murine models
have shown that tumors in vivo, initiated by a single
oncogene, remain ‘‘addicted’’ to that initiating oncogene
and die by apoptosis when its expression is suppressed
(reviewed in Refs. [12,13]). In ‘‘rewiring’’ the cell by
expression of the initiating oncogene, clearly cell survival
becomes compromised. Proliferation remains dependent on
continued oncogene overexpression but necessarily in the
context of a changed pattern of survival. This phenomenon
of oncogene addiction, to the original oncogenic event,
was independent of the character of the initiating onco-
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or ras or Bcr-Abl, and all were ‘‘cured’’ of their tumors by
suppression of oncogene expression.3. The interplay of apoptosis and proliferation and
environment in cancer pathogenesis
There is now a well-defined coupling between cell
proliferation and cell death. Indeed, most mechanisms
leading to cell proliferation, including deregulated expres-
sion of c-Jun, deregulated expression of c-Myc and virtually
any pathway that would lead to the activation of the
transcription factors of the E2F family have also the ability
to promote apoptosis [14]. Thus, a mitogenic lesion endan-
gers the affected cells, as exemplified by the spectacular
apoptosis that accompanies c-Myc activation in pancreatic h
cells [11]. A cell whose proliferation is deregulated has to
escape from apoptosis in order to expand and form a tumor.
An anti-apoptotic ‘‘platform’’ is thus fundamental to tumor
initiation, progression and maintenance. A great number of
cancer cells exhibit anti-apoptotic mutations (see below). An
expanding cancer cell population has also to modify its
surrounding milieu, as it is replicating outside of its nor-
mally adequate environment which provides anti-apoptotic
signals. These signals normally come from soluble factors,
physical interactions with the neighbouring cells or with the
extracellular matrix. Moreover, tumor progression is accom-
panied by a certain number of stress signals that promote
apoptosis, such as nutrient deprivation, hypoxia or telomere
erosion. Not surprisingly, therefore, evasion of apoptosis is a
fundamental hallmark of cancer [15].
Understandably, the fact that cancer cells are under
strong selective pressure to evade apoptosis casts doubt
on the use of empirical apoptotic triggers in order to
eradicate them [16]. Anti-apoptotic lesions that can allow
a neoplastic cell to survive also render cancer cells
resistant to many classical cancer therapeutics, whose goal
is mainly to produce an apoptotic response [17]. Because
cancer cells are continuously under the pro-apoptotic
influence of both their deregulated proliferation and ectop-
ic growth, they are inherently sensitized to apoptosis
despite their acquired pro-survival lesions. As a result,
they may be acutely dependent upon those mutations to
survive: shrewd inhibition of an anti-apoptotic pathway
may thus be potently harmful to a cancer cell, while hardly
affecting a normal cell safely protected by its trophic
niche. This justifies new therapeutic strategies aiming to
target the aberrant mechanism of survival of cancer cells.
In that respect, a better characterization of the molecular
pathways of apoptosis, and of the defects in such pathways
that cancer cells exhibit, will lead not only to efficient, but
also to specific, anti-cancer therapy: the pathology itself is
used as the ‘‘driver’’ for cell death. The key question arises
as to how many survival pathways and proteins might
need to be targeted by drugs?4. The Bcl-2 family of proteins are at an apical point of
the apoptotic machinery
Strategies which target either survival signaling or the
activation of tumor suppressor activity all act at some point
of diversity in the cell death pathway. Therefore, their
success can be strongly hampered by defects in the apopto-
tic machinery itself. The Bcl-2 family members that regulate
apoptosis and mitochondrial integrity [18] are at the apex of
the decisional ‘‘life or death’’ tree, and present a limited
number of key targets for therapeutic intervention. Among
the Bcl-2 family members, the pro-apoptotic Bax and Bak
display sequence conservation throughout three Bcl-2 ho-
mology domains (BH1 to 3). Once they are in an active
conformation, these multi-domain pro-apoptotic proteins are
intrinsically cytolytic. Both have the innate ability to perturb
the membrane permeability of mitochondria where they
localize. This results in the release of numerous apoptogenic
proteins (such as, for instance, cytochrome c) from the
mitochondrial intermembrane space, by a mechanism that
is still debated [19,20]. In addition, Bax and Bak may
control apoptosis at the endoplasmic reticulum (ER), where
they also reside, by regulating ER Ca2 +-dependent apopto-
tic stimuli [21].
The deleterious effects of Bax/Bak are counterbalanced
by the anti-apoptotic activity of survival members such as
Bcl-2, Bcl-xL or Mcl-1 that display all four Bcl-2 homology
domains (BH1 to 4) and the ratio between anti-apoptotic and
multi-domain pro-apoptotic Bcl-2 family members helps
determine the cellular susceptibility to death stimulation
[22]. Anti-apoptotic Bcl-2 family members localize at the
mitochondria, where they can prevent the release of apopto-
genic factors that otherwise occurs in response to apoptotic
stimuli. They also reside at the ER, and they could play a
role in regulating ER Ca2 + dynamics [23]. The protective
function of Bcl-2/Bcl-xL appears to be, in great part, built
upon their faculty to form inactivating heterodimers with
Bax/Bak [24]. As discussed below, these proteins may
nevertheless exert some of their survival effects indepen-
dently from this sequestering function.
A third subgroup of pro-apoptotic Bcl-2 family members
display sequence homology only with the BH3 domain [25].
These BH3-only proteins bind to, and functionally antago-
nize, Bcl-2/Bcl-xL via their eponymous homology domain.
They seem to act as the afferent effectors of various pro-
apoptotic signals, integrating them into one single death
pathway mainly mediated by the multi-domain proapoptotic
Bax and Bak [26–28]. Ectopic expression of either Bcl-2 or
Bcl-xL, or the combined genetic ablation of both Bax and
Bak, renders cells resistant to a great variety of apoptotic
stimuli, unambiguously showing that the Bcl-2 family
members guard a necessary gateway to apoptosis.
An imbalance among the Bcl-2 family of proteins, in
favor of the anti-apoptotic members, is a phenomenon that
naturally, and frequently, occurs in cancer cells. Indeed,
overexpression of anti-apoptotic Bcl-2 or Bcl-xL probably
P. Juin et al. / Biochimica et Biophysica Acta 1644 (2004) 251–260 253occurs in more than half of all cancers. Moreover, loss of
expression of Bax is also found in some colorectal cancers
and in hematopoietic malignancies [29,30], whereas the
expression of a highly apoptogenic variant of Bax is
correlated with an increased survival of glioblastoma multi-
forme patients [31]. Those defects may arise, at least in part,
from the fact that neoplastic cells are under strong selective
pressure to stabilize their mitochondrial permeability, even
if they harbor alterations in the p53 tumor surveillance
pathway. c-Myc, for instance, can induce mitochondrial
damage independently from the transcriptional activity of
p53 [32,33]. Since p53 also activates the mitochondrial
death pathway, the mitochondrion appears to integrate the
diverse pro-apoptotic mechanisms induced by oncogenes.
This integrative role is a key feature promoting the mole-
cules as potential therapeutic targets. Studies in transgenic
mice have indeed revealed that Bcl-2 (and/or Bcl-xL) over-
expression and p53 mutations (or ARF loss) are selected for
independently during Myc-induced lymphomagenesis [34].
Unfortunately, such defects will also hinder the effi-
ciency of most therapies that aim at inducing apoptosis in
cancer cells, as they all rely on a Bcl-2-dependent pathway
to exert their deleterious effects (even including those
based on the stimulation of the death receptor pathway:
see Ref. [35] and references therein). Thus, new strategies
need to be developed in order to tackle the cytoprotective
activity of Bcl-2/Bcl-xL.5. The therapeutic strategies
5.1. Gene therapy and antisense approaches
One current approach uses gene therapy-based delivery
of Bax [36,37]. Recombinant adenoviruses encoding for
Bax are highly toxic, even to healthy cells (see Ref. [36] and
references therein). This approach therefore requires opti-
mization as expression of the transgene has to be selectively
targeted to transformed cells. This can be achieved with the
use of a recombinant adenovirus in which Bax expression is
driven by the human telomerase reverse transcriptase pro-
moter. This adenovirus was shown to induce Bax expression
selectively in cancer cells (and thus to diminish the second-
ary effects on healthy cells) and to eradicate tumor growth in
xenograft models [38].
The use of nuclease resistant antisense oligonucleotides
targeting the Bcl-2 mRNA has reached to Phase III clinical
trials for melanoma, myeloma, acute myeloid leukaemia and
chronic lymphatic leukaemia [39]. Experiments in vitro and
in mouse models have shown that BCL-2 antisense
increases the sensitivity to conventional chemotherapeutics,
and phase II data indicate that the combination of the
antisense approach and of chemotherapy may increase
therapeutic success. Other antisense-based strategies have
been developed. These include the use of either BCL-XL, or
MCL-1 antisense oligonucleotides [40], the use of BCL-Xantisense oligonucleotides designed to shift pre-mRNA
splicing away from producing the anti-apoptotic Bcl-xL
protein to the proapoptotic one Bcl-xS [41] or that of
BCL-2/BCL-XL bispecific antisense oligonucleotides [42].
Even if some of these approaches were promisingly shown
to induce apoptosis in some tumor cells, or to sensitize them
to chemotherapy in vitro, there is still some uncertainty as to
which, if any, of these anti-apoptotic proteins (that are
frequently co-expressed in cancer cells) is the most impor-
tant survival factor for one given tumor type. This chal-
lenging question is complicated by the fact that some of the
Bcl-2 family members may exert, in cancer cells, functions
that differ from their anti-apoptotic one. Bcl-2 and Bcl-xL
have both been found to regulate the cell cycle by a
mechanism that is still debated [43,44]. Thus, antisense
oligonucleotides may have an unwanted proliferative effect
in certain cells [45]. Along this line, it is also important to
note that high Bcl-2 expression correlates with good prog-
nosis in breast cancers (see Ref. [46] and references therein).
Although the mechanism involved in this paradoxical effect
of Bcl-2 is yet to be characterized, it indicates, to the very
least, that down-regulating certain anti-apoptotic Bcl-2 fam-
ily members may not always be appropriate.
5.2. Targeting Bcl-2 and Bcl-XL with peptides
An alternative approach to counter the protective effects
of Bcl-2/Bcl-xL is to try to directly antagonize some of the
survival functions of these proteins. The three-dimensional
analysis of Bcl-xL [47] and Bcl-2 [48] has revealed an
hydrophobic pocket at the surface of these proteins, formed
by their BH1, -2 and -3 domains. These domains are all
necessary for the survival function of the anti-apoptotic Bcl-
2 members, and the hydrophobic groove they form plays an
important role in their inhibitory binding to pro-apoptotic
counterparts. In particular, it appears that this site serves as a
recipient for the conserved BH3 domain of BH3-only
proteins. This suggests that synthetic peptides encompassing
minimal BH3 domains may be used as a basis to develop
functional antagonists of Bcl-2/Bcl-xL, which would pre-
vent the sequestration of pro-apoptotic members by these
survival proteins.
Experiments using either unmodified, microinjected,
peptides or peptides attached to cell permeant moieties of
either lipidic [49] or peptidic [50] origin have shown
promising results with respect to cancer therapy. First,
peptides indeed bind to survival proteins of the Bcl-2 family
[47], antagonize their protective activity against death-
receptor or DNA-damage induced apoptosis [50,51] and
are cytolytic per se [49,51,52]. Second, c-Myc activation in
primary murine cells increases their sensitivity to apoptosis
induction by BH3 peptides [51]. The molecular mechanism
involved remains to be characterized, and it would also be
important to know whether this effect extends to other
mitogenic lesions. This suggests, nevertheless, that cancer
cells may be intrinsically sensitized to the deleterious effects
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ability of some cell permeant BH3 peptides to induce
apoptosis in human myeloid leukemia in vitro, slowing
their growth in immunodeficient mice, while having little
effect on normal peripheral blood lymphocytes [49]. Third,
the ability of BH3 peptides, and their ability to cooperate
with c-Myc, is intact in p53-deficient cells [51]. Thus, in
cells harboring a deficient p53 pathway, peptidic antagonists
of Bcl-2/Bcl-xL represent an alternative to the aforemen-
tioned antisense approach, which is essentially used in
combination with classical chemotherapy, and whose effi-
ciency may be altered by p53 deficiency [53]. Fourth,
specific induction of apoptosis by BH3 peptides requires
the presence of either one of the two multi-domain pro-
apoptotic proteins Bax or Bak [51]. This is also of potential
interest, as cancer cells that exhibit a loss in Bax expression
usually retain Bak expression. The sole loss of Bax may
thus significantly lower their apoptotic response, but re-
cruitment of Bak activity by the use of a small BH3 peptide
may restore sensitivity to apoptosis [51].
At the very least, these observations constitute a proof of
concept validating strategies based on generating molecules
that occupy the BH3 binding pocket of Bcl-2/Bcl-xL. As all
the binding information in BH3 domains is derived from
one short contiguous sequence, one possible approach is toFig. 1. Small molecule inhibitors of Bcl-2/Bcl-xL. (A) Structure of some of the co
xL. The optimized structure of Bcl-xL (pdb 1BXL) is represented by its Connolly
histidines region. The surface formed by residues from the conserved BH1, BH2 an
rest of the surface is in white. The hydrophobic cleft is formed by residues from B
models; the carbon, oxygen, nitrogen, sulfur and halogens are colour-coded in whi
b, complex with HA-14-1; c, complex with BH3-i1; d, complex with BH3-i2; e, N
optimized). All structures were modeled in SYBYLR 6.9. All the hydrogen ato
geometries were optimized using the Tripos force field, using Kollman charges on
Each compound was then docked manually in this binding cavity and its conforma
kept fixed in aggregate, except the side chains of the amino acid residues of the g
conformations during the optimization. TRIPOS ASSOCIATES Inc., 1699 S. Hadesign mimetics of the peptide inhibitors. There is no such
peptidomimetic described so far, but the modified molecules
should exhibit increased cell permeability and increased
stability when compared to the peptides they are derived
from, which are poorly cell permeant per se and, presum-
ably, highly unstable given their short a-helical structure.
Moreover, the helical structure of BH3 peptides may also be
troublesome, as a-helices can often be nonselectively toxic
to cells: mutant BH3 peptides that lack the ability to bind to
Bcl-2/Bcl-xL exhibit a weak, nonspecific cytotoxicity [51].
Although this modest effect can be easily differentiated
from the stronger effects specifically elicited by wild type
BH3 peptides in model experiments, it may limit the
usefulness of BH3-peptides in vivo. One alternative ap-
proach to overcome this possible problem is to discover
small-molecule, nonpeptide Bcl-2/Bcl-xL antagonists.
5.2.1. Small molecule antagonists of Bcl-2 and Bcl-XL
To date, more than a dozen compounds that may antag-
onize Bcl-2/Bcl-xL have been described (reviewed recently
in Refs. [54–56]). A selection of such small molecule
inhibitors of Bcl-2 or Bcl-XL is shown in Fig. 1A.
Among these, some have been initially discovered from
in silico screens based on the predicted structures of the
BH3 binding site of either Bcl-2 or Bcl-xL [57,58]. Thempounds discovered so far. (B) Molecular models of ligands bound to Bcl-
Surface. The entire protein is shown except for the disordered C-terminal
d BH3 domains are colour-coded in yellow, red and green, respectively. The
H1, BH2 and BH3 domains. The apoptotic ligands are represented by stick
te, red, blue, yellow and green, respectively. a, complex with Antimycin A1;
MR original complex with the BH3 domain of the Bak protein (1BXL non-
ms were added on the NMR structure pdb1BXL of the protein and their
all atom of the protein and Gasteiger–Hu¨ckel charges on the ligand atoms.
tion was fully optimized with Tripos force field, while the whole protein was
roove in close contact with the ligands which were allowed to change their
nley Road, Saint Louis, Missouri 63144, USA.
Fig. 1 (continued ).
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binding of a BH3 peptide to Bcl-2 was monitored in a
polarization fluorescence assay [57]. Moreover, this com-
pound selectively induces apoptosis in malignant hemato-
poietic cell lines that overexpress Bcl-2 [59], in agreement
with the notion that it acts as a direct inhibitor of this
protein. It has been proposed, moreover, that Bax expression
is a key determinant of its cytotoxic effect [60]. Enyedy et
al. [58] have characterized other small compounds that alsoprevent binding of Bcl-2 to a BH3 peptide, bind directly to
Bcl-xL as assayed by NMR and selectively induce apoptosis
in cancer cells with high levels of Bcl-2.
Other compounds were found in a more straightforward
screen for molecules that can disrupt the complex between
Bcl-xL and a BakBH3 peptide. Degterev et al. [61] have
identified by this approach novel small molecules, BH3Is,
that, as revealed by NMR studies, can occupy the BH3
binding domain of Bcl-xL, disrupting interactions between
P. Juin et al. / Biochimica et Biophys256the latter and its pro-apoptotic counterparts in vivo, and
inducing apoptosis. BH3Is molecules have also been used
in a ligand optimization method that combines structural
and computational approaches and that has led to the
discovery of other potential inhibitors [62]. A polarization
fluorescence-based assay similar to the one used by
Degterev and coworkers has also been used in order to
screen for natural products. Kitada et al. [63] have char-
acterized certain polyphenols as such inhibitors. Gossypol
and Purpurogallin were shown to bind to the hydrophobic
pocket of Bcl-xL by heteronuclear NMR spectroscopy
techniques. The former exhibits the ability to induce
apoptosis, even in Bcl-xL overexpressing cells, whereas
the latter is much less efficient, presumably as a conse-
quence of its hydrophylic character. Chan et al. [64] have
also characterized chelerythrin, a compound previously
known as a protein kinase C inhibitor, as a compound
that can inhibit binding of Bcl-xL to either a BH3 peptide
or full-length Bax and that can induce apoptosis in cells
overexpressing Bcl-xL by directly triggering mitochondrial
permeabilization.
Antimycin A, an inhibitor a respiration, was fortuitously
characterized as a Bcl-xL inhibitor through its ability to
induce apoptosis in Bcl-xL overexpressing cells [65]. Fur-
ther studies have shown that this compound, or a derivative
thereof that lacks the ability to inhibit respiration, prevents
the binding of a BH3 peptide to recombinant Bcl-2 and
induces mitochondrial permeabilization.
All the aforementioned molecules were discovered by
approaches that focus on the structure, or the function, of the
BH3 binding site of anti-apoptotic Bcl-2 family members.
No obvious structural consensus arises from the highly
diverse molecules discovered so far (see Fig. 1A), and it
also appears that their respective binding to the hydrophobic
pocket of their target may involve distinct structures (see
Fig. 1B). All of these molecules nevertheless seem to
recapitulate some of the functional effects of BH3 peptides,
in as much as they can bind to either Bcl-xL or Bcl-2,
disrupt heterodimers these form with pro-apoptotic counter-
parts, and induce apoptosis. Antimycin Awas shown to bind
to both Bcl-xL [65] and Bcl-2 [66], despite the structural
differences in the respective surface pockets of these pro-
teins [48]. It is, however, unclear whether compounds that
were specifically selected for their ability to bind one anti-
apoptotic Bcl-2 member will also antagonize the others.
Most of the current molecules exhibit a disappointingly low
affinity for their targets, thus raising doubts on the speci-
ficity with which they induce apoptosis. However, a report
of a molecular scaffold, mimicking the alpha-helix of the
BH3 domain of Bak, has provided an inhibitor with a KD of
114 nM, measured in a Bak peptide-Bcl-XL binding assay
[67]. These types of molecules are templates for drug
design, and modifications improving their biological activ-
ity are required before the balance between their anti-tumor
activity and their side effects against normal cells can be
evaluated.5.3. Mechanistic questions—how well do we understand the
dynamics of Bcl-2 protein family interactions?
Even though BH3 mimetics with high efficiency could
be developed using peptides or small molecules as lead
compounds, there are still some urgent issues that need to be
addressed. The first issue stems from our relatively poor
understanding of how BH3-only proteins promote apopto-
sis. Evolving evidence indicates that these proteins, as well
as BH3 peptides, induce apoptosis by a mechanism that
requires the presence of either Bax of Bak. In viable cells,
these multi-domain proteins appear as inactive proteins
residing at the mitochondria (Bak) or in the cytosol (Bax)
[68]: they need to undergo a change in their conformation to
exert their apoptotic function. Thus, in order to induce Bax/
Bak dependant apoptosis, a certain signal has to activate
these proteins in some way. Certain BH3 peptides seem to
have the ability to directly activate those proteins and allow
their pro-apoptotic assembly in the mitochondrial membrane
[69]. It is therefore possible that certain BH3 mimetics may
have the ability to directly activate Bax/Bak and function as
death agonists (Fig. 2). It has to be stressed, however, that
occupancy of the surface pocket of the Bcl-2 family
members and ligand-induced activation of Bax/Bak seem
to display distinct structural requirements: some other BH3
peptides [69] or even small molecules antagonists of Bcl-2/
Bcl-xL [70] seem to lack the ability to activate Bax/Bak. As
the latter compounds nevertheless induce apoptosis, it seems
important to understand whether, and how, such survival
antagonists recruit Bax/Bak activity by inhibiting Bcl-2/Bcl-
xL. One possibility is that they can release from their anti-
apoptotic targets some intermediate death agonists that, in
turn, lead to Bax/Bak activation (Fig. 2). It should be noted,
however, that despite its inability to self-associate, Bax was
shown to interact with Bcl-xL in model experiments [71].
Peptidic antagonists of Bcl-xL, moreover, release from such
complexes active forms of Bax. Therefore, survival antag-
onists may promote the pro-apoptotic assembly of activated
Bax without any other intermediaries than Bcl-2/Bcl-xL
themselves (Fig. 2), by a mechanism in which, most
intriguingly, anti-apoptotic proteins would cooperate with
their antagonists to induce apoptosis [71].
Along this line, the fact that Bcl-2 and Bcx-L over-
expressing cells are highly sensitized to apoptosis induction
by antimycin A [65,66] is striking. It will be of interest to
know whether other small molecule inhibitors of Bcl-2/Bcl-
xL recapitulate this effect, but it is obvious that deciphering
the mechanism involved may lead to the development of
attractive strategies that are selectively efficient against
cancer cells that overexpress Bcl-2 or Bcl-xL. One straight-
forward approach towards the characterization of the mode
of action of any given molecule may be the identification of
the proteins, in one given cell type, that this compound
releases from Bcl-2/Bcl-xL. It should be noted, moreover,
that posttranslational modifications, such as that induced by
proteolytic cleavage, can convert Bcl-2 or Bcl-xL into
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Fig. 2. Modes of activation of the pro-apoptotic multi-domain proteins Bax/Bak by BH3-like molecules. Certain BH3 mimetics may function, like the BH3
domain of Bid, as ‘‘death agonists’’ (red star) that directly trigger the activation of Bax and Bak (A). Anti-apoptotic proteins interfere with this process by
inhibiting activated Bax/Bak or by directly binding to the death agonists. Other BH3-like molecules may, in a similar manner as the BH3 domain of Bad,
function as ‘‘survival antagonists’’ that only interact with Bcl-2/Bcl-xL (pink stars). They may induce apoptosis by provoking the release from Bcl-2/Bcl-xL of
an endogenous death agonist (red star in B) that in turn activates Bax/Bak, as proposed in Ref. [28]. Alternatively (C), such survival antagonists may promote
apoptosis without the involvement of an intermediate agonist, by directly releasing an active Bax from heterodimers with anti-apoptotic proteins [71]. See text
for further details.
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ly possible that certain ligands of Bcl-2/Bcl-xL may suffi-
ciently alter the conformation of these proteins to turn them
into pro-apoptotic effectors, even though there is, to date, no
evidence for such putative effect.
5.4. Possible pitfalls
It is uncertain whether induction of apoptosis by Bcl-2
antagonists will be efficient in all cancer cells. If such
antagonists function as true BH3 mimetics, then changes
in the conformation of Bax (and of Bak), its relocation from
cytosol to mitochondria and its oligomerization in the
mitochondrial membrane should be important for the initi-
ation of apoptosis by such molecules. However, recent
evidence indicates that none of these changes are alone
sufficient to commit a taxol-resistant neuroblastoma cell line
to apoptosis [74]. The defect that these cells display is yet to
be characterized, but it appears to result in limited mito-
chondrial damage and cytochrome c release in response to
an apoptotic stimulus. The fact that the stores of cytochrome
c are heavily subcompartimentalized within healthy mito-
chondria has led to suggest that a profound remodelling of
mitochondria is involved in the complete cytochrome c
release observed in apoptotic cells (see Ref. [75] and
references therein). Surprisingly, the BH3 only protein Bid
induces dramatic changes in the inner membrane shape ofmitochondria that could participate in the complete release
of cytochrome c that this protein triggers. This effect is
independent from the BH3 domain of Bid and does not
require Bax and Bak, even though these two proteins are
necessary for Bid to induce full apoptosis (see Ref. [76] and
references therein). Other candidates for the reorganization
of mitochondrial structure that occurs during apoptosis are
proteins that physiologically shape the mitochondrial retic-
ulum, as exemplified by the finding that a dominant
negative form of Drp-1, a dynamin family protein normally
involved in mitochondrial fission, interferes with apoptosis
induction [77]. Defects in these ill-characterized mitochon-
drial remodelling pathways may strongly hamper the effi-
ciency with which Bcl-2 inhibitors promote apoptosis.
Another issue is raised by the complex relationship
between pro-apoptotic Bcl-2 family members and caspases.
Genetic ablation of caspases (caspase 9 and caspase 3),
which act downstream of cytochrome c release, seems
insufficient to promote resistance to cell death induction
by ectopic expression of BH3-only proteins [28]. Moreover,
the broad spectrum inhibitor of caspases zVADfmk had no
significant effect on the onset of apoptosis and cytochrome c
release induced by microinjected BH3 peptides [51], while
significantly extending the execution phase of apoptosis (as
assayed by time lapse video-microscopy). However, recent
evidence, using specific silencing of other individual cas-
pases [78] or a more potent caspase inhibitor [79], indicates
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drial death pathway. One implication from these observa-
tions is that, although some caspases may be dispensable for
the cytotoxic effects of BH3 mimetics, others may play an
essential role in the efficiency with which they promote
apoptosis. Many cancer cells overexpress inhibitors of
apoptosis protein (IAPs) that can endogenously quell the
activity of some caspases. Silencing of some IAPs by
specific antisense oligonucleotides has been shown to in-
duce apoptosis in some cancer cells, or to sensitize them to
chemotherapy, indicating that overexpressed IAPs may
significantly impact on the cellular response to apoptosis.
IAPs can be functionally antagonised by small peptides
derived from a tetrapeptidic motif in Smac that binds to the
BIR domains of IAPs. Although Smac is considered to
function as a dimer [80], such monomeric Smac peptides
exhibited a remarkable ability to sensitize various tumor
cells, both in vitro and in vivo, to apoptosis induced by
death receptor ligation or chemotherapy. They bypass the
survival effects of Bcl-2 or xIAP without significantly
altering normal cells [35]. Smac agonists are thus promising
cancer therapeutics that may be extremely useful when
combined with a cancer-specific cytotoxic therapy. It will
be of great interest, in particular, to evaluate their functional
interaction with Bcl-2 antagonists in resistant tumors.
Most strikingly, Bcl-2 appears to suppress the caspase
activation program that was reported to function upstream
of mitochondria by Marsden et al. [79]. Another implica-
tion from this is that Bcl-2 may be directly involved in
protein–protein interactions with a ‘‘caspasomal’’ com-
plex, pretty much in the same way as its C. elegans
equivalent, CED9, interacts with the scaffolding protein
CED4. A CED4-like equivalent that could bind to Bcl-2 is
yet to be characterized in mammals, but, if it exists, its
displacement from Bcl-2 may play a key role in apoptosis
induction. As a result, the ability of various BH3 mimetics
to disrupt complexes between Bcl-2 and this unknown
CED4-like protein (in a similar manner as the C. elegans
BH3-only protein Egl-1 does) could be one major param-
eter. Along this line, it is also important to note that Bcl-2/
Bcl-xL has been reported to interact with numerous
proteins that do not contain a BH3 domain (such as R-
Ras, Raf-1, calcineurin; reviewed in Ref. [81]). Thus,
although the potent pro-apoptotic activity of BH3-mimetics
(see above) suggests that sequestering BH3-containing
proteins is one major way by which Bcl-2/Bcl-xL protects
cells from apoptosis, other functions of Bcl-2/Bcl-xL may
not be abrogated by certain BH3 mimetics.
Finally, the question of the degree of in vivo selectivity
possible for molecules targeted to perturb Bcl-2/Bcl-xL
function may depend not only on the extra requirements
of a tumor to support its survival via these molecules. It may
also depend on the role that Bcl-2/Bcl-xL plays in main-
taining not only normal cell survival but other, homeostatic,
functions of the cell. Recent work has shown that Bcl-xL
may play a role in controlling the synaptic response andstability of certain neurons by facilitating ATP flux across
the mitochondrial membrane [82]. Thus, strategies targeted
to alter Bcl-2/Bcl-xL function may have secondary effects
outside the domain of apoptosis.6. Conclusions
The recent and spectacular success of the tyrosine kinase
inhibitor GlivecR in the clinic has confirmed that novel
drugs can be effective and selective if targeted to a molec-
ular lesion implicated in the pathology. In the case of
GlivecR-sensitive chronic myelogenous leukemia, this is
the Bcr-Abl oncogene. Is targeting a defined single molec-
ular lesion going to be possible in colon cancer? This is
debatable. We suggest here that targeting the survival
platform of tumor cells, a platform that underpins their
ability to carry mutations, genetic instability and aberrant
oncogene expression, may be tumor selective. With the Bcl-
2 family of proteins at the pinnacle of the ‘‘decision
network’’ for death and survival (as the finding that the
double knockout of the pro-apoptotic proteins Bax and Bak
renders cells pleotropically resistant to stress, suggests),
there is also hope that the number of drug targets will be
limited, while selectivity would come from the inherent
differences between tumor and normal cells, reflected in
their load of genomic damage and inappropriate expression
of oncogenes. Using the general features of the molecular
pathology of cancer as the driver of cell death is indeed
attractive. Like all hopes for a more selective therapy of
cancer, time and biology will be the arbiters.Acknowledgements
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